Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Renal Cell Carcinoma-Pipeline Review, H1 2015

Renal Cell Carcinoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Renal Cell Carcinoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Renal Cell Carcinoma-Pipeline Review, H1 2015', provides an overview of the Renal Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 11

Introduction 12

Global Markets Direct Report Coverage 12

Renal Cell Carcinoma Overview 13

Therapeutics Development 14

Pipeline Products for Renal Cell Carcinoma-Overview 14

Pipeline Products for Renal Cell Carcinoma-Comparative Analysis 15

Renal Cell Carcinoma-Therapeutics under Development by Companies 16

Renal Cell Carcinoma-Therapeutics under Investigation by Universities/Institutes 24

Renal Cell Carcinoma-Pipeline Products Glance 26

Late Stage Products 26

Clinical Stage Products 27

Early Stage Products 28

Unknown Stage Products 29

Renal Cell Carcinoma-Products under Development by Companies 30

Renal Cell Carcinoma-Products under Investigation by Universities/Institutes 39

Renal Cell Carcinoma-Companies Involved in Therapeutics Development 40

Acceleron Pharma, Inc. 40

Advenchen Laboratories, LLC 41

Altor BioScience Corporation 42

Ambrx, Inc. 43

Amgen Inc. 44

Ampio Pharmaceuticals, Inc. 45

Angiogene Pharmaceuticals Limited 46

arGEN-X BV 47

Argos Therapeutics, Inc. 48

Astellas Pharma Inc. 49

Bayer AG 50

Beta Pharma, Inc. 51

Bio-Cancer Treatment International Limited 52

Biogenomics Limited 53

Bionomics Limited 54

Boehringer Ingelheim GmbH 55

Boston Biomedical, Inc. 56

Bristol-Myers Squibb Company 57

Caladrius Biosciences, Inc. 58

Calithera Biosciences, Inc. 59

Celldex Therapeutics, Inc. 60

Celltrion, Inc. 61

Cerulean Pharma, Inc. 62

Chipscreen Biosciences Ltd 63

Conkwest, Inc. 64

CureTech Ltd. 65

Cytune Pharma SAS 66

Eisai Co., Ltd. 67

Eli Lilly and Company 68

Epirus Biopharmaceuticals, Inc. 69

Exelixis, Inc. 70

F. Hoffmann-La Roche Ltd. 71

Genor BioPharma Co., Ltd. 72

GenSpera, Inc. 73

GlaxoSmithKline Plc 74

Hemispherx Biopharma, Inc. 75

Hospira, Inc. 76

Hutchison MediPharma Limited 77

immatics biotechnologies GmbH 78

Immune Design Corp. 79

Immunicum AB 80

ImmunoGen, Inc. 81

Inbiopro Solutions Pvt. Ltd. 82

InteRNA Technologies B.V. 83

Jiangsu Hengrui Medicine Co., Ltd. 84

KAHR medical Ltd. 85

Karyopharm Therapeutics, Inc. 86

Kyowa Hakko Kirin Co., Ltd. 87

Lpath, Inc. 88

Mabion SA 89

MacroGenics, Inc. 90

MediaPharma s.r.l. 91

MediGene AG 92

MedImmune, LLC 93

Merck & Co., Inc. 94

Millennium Pharmaceuticals, Inc. 95

Mologen AG 96

NewLink Genetics Corporation 97

Novartis AG 98

Omeros Corporation 99

Oncobiologics, Inc. 100

OncoMax 101

Ono Pharmaceutical Co., Ltd. 102

Onyx Pharmaceuticals, Inc. 103

Panacea Biotec Limited 104

Panacela Labs, Inc. 105

Peloton Therapeutics, Inc. 106

Pfizer Inc. 107

Pono Pharma 108

Prima BioMed Ltd. 109

PsiOxus Therapeutics Limited 110

Rexahn Pharmaceuticals, Inc. 111

Seattle Genetics, Inc. 112

Syndax Pharmaceuticals, Inc. 113

Taiwan Liposome Company, Ltd. 114

TC BioPharm Limited 115

Theravectys S.A. 116

Threshold Pharmaceuticals, Inc. 117

TRACON Pharmaceuticals, Inc. 118

TVAX Biomedical, Inc. 119

Vascular Biogenics Ltd. 120

Renal Cell Carcinoma-Therapeutics Assessment 121

Assessment by Monotherapy Products 121

Assessment by Combination Products 122

Assessment by Target 123

Assessment by Mechanism of Action 129

Assessment by Route of Administration 134

Assessment by Molecule Type 136

Drug Profiles 138

afuresertib hydrochloride + trametinib dimethyl sulfoxide-Drug Profile 138

AGS-003-Drug Profile 139

AGS-16C3F-Drug Profile 142

AL-2846-Drug Profile 143

AL-3818-Drug Profile 144

AL-8326-Drug Profile 146

aldesleukin-Drug Profile 147

alpelisib-Drug Profile 148

ALT-803-Drug Profile 150

AM-0010-Drug Profile 152

AMG-172-Drug Profile 153

apatinib-Drug Profile 155

APVAC-1-Drug Profile 158

ARGX-110-Drug Profile 160

atezolizumab-Drug Profile 163

Autologous Cell Therapy for Cancer and Viral Infections-Drug Profile 167

axitinib-Drug Profile 168

BBI-503-Drug Profile 171

BC-2059-Drug Profile 173

BCT-100-Drug Profile 175

bevacizumab biosimilar-Drug Profile 177

bevacizumab biosimilar-Drug Profile 178

bevacizumab biosimilar-Drug Profile 179

bevacizumab biosimilar-Drug Profile 180

bevacizumab biosimilar-Drug Profile 181

bevacizumab biosimilar-Drug Profile 182

bevacizumab biosimilar-Drug Profile 183

bevacizumab biosimilar-Drug Profile 184

bevacizumab biosimilar-Drug Profile 185

BNC-105-Drug Profile 186

BNC-105P-Drug Profile 187

BPI-3119-Drug Profile 189

cabozantinib s-malate-Drug Profile 190

capmatinib-Drug Profile 193

carfilzomib-Drug Profile 196

CB-839-Drug Profile 200

CDX-014-Drug Profile 202

Cell Therapy for Renal Cancer-Drug Profile 203

Cell Therapy to Target FMNL1 for Cancer-Drug Profile 204

crizotinib-Drug Profile 205

CRLX-101-Drug Profile 209

CS-2164-Drug Profile 211

CST-101-Drug Profile 212

CYP-0150-Drug Profile 214

dalantercept-Drug Profile 215

Dendritic Cell Therapy for Metastatic Renal Cell Carcinoma and Melanoma-Drug Profile 217

Dendritic Cell Therapy for Oncology and Infectious Disease-Drug Profile 218

Dendritic Cell Therapy for Renal Cell Carcinoma-Drug Profile 219

Dendritic Cell Therapy for Renal Cell Carcinoma-Drug Profile 220

Dendritic Cells + Cytokine Induced Killer Cells-Drug Profile 221

denenicokin-Drug Profile 222

DMS-612-Drug Profile 224

emibetuzumab-Drug Profile 225

enadenotucirev-Drug Profile 226

enoblituzumab-Drug Profile 228

entinostat-Drug Profile 230

everolimus-Drug Profile 234

evofosfamide-Drug Profile 240

G-305-Drug Profile 248

HMPL-504-Drug Profile 250

IBPM-002BZ-Drug Profile 252

IMA-901-Drug Profile 253

IMP-321-Drug Profile 255

interferon alfa-2b (recombinant)-Drug Profile 257

Intuvax-Drug Profile 258

ipilimumab-Drug Profile 260

KAHR-101-Drug Profile 264

KPT-251-Drug Profile 265

lenvatinib-Drug Profile 266

LT-1009-Drug Profile 271

LY-2510924-Drug Profile 275

MDNA-55-Drug Profile 276

MEDI-0680-Drug Profile 277

MGN-1601-Drug Profile 278

MicroRNA-7 for GBM and Renal Cell cancer-Drug Profile 280

mipsagargin-Drug Profile 281

mirvetuximab soravtansine-Drug Profile 283

MK-2206-Drug Profile 285

Monoclonal Antibody Conjugated to Target Cells Expressing Antigen G250 for Renal Cell Carcinoma-Drug Profile 288

Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma-Drug Profile 289

MPHE-001B-Drug Profile 290

MPHE-001C-Drug Profile 291

MVAME-03-Drug Profile 292

NCE-001-Drug Profile 293

nintedanib-Drug Profile 294

nivolumab-Drug Profile 299

OMRCA-01-Drug Profile 305

Orellanine-Drug Profile 307

panobinostat-Drug Profile 308

pazopanib hydrochloride-Drug Profile 314

pazopanib hydrochloride + pembrolizumab-Drug Profile 320

pembrolizumab-Drug Profile 321

pexastimogene devacirepvec-Drug Profile 329

PF-04518600-Drug Profile 331

pidilizumab-Drug Profile 332

Protein for Renal Cell Carcinoma-Drug Profile 334

PT-2385-Drug Profile 335

radium Ra 223 dichloride-Drug Profile 336

Recombinant Protein for Oncology-Drug Profile 339

regorafenib-Drug Profile 340

rilotumumab-Drug Profile 343

rintatolimod-Drug Profile 345

rSIFN-co-Drug Profile 346

RX-0201-Drug Profile 347

RX-3117-Drug Profile 349

sapanisertib-Drug Profile 350

SF-1126-Drug Profile 352

SGN-CD70A-Drug Profile 354

SHR-1020-Drug Profile 355

Small Molecule to Target GPR65 for Cancer and Inflammatory Disorders-Drug Profile 357

Small Molecules to Activate AMPK for Renal Cell Carcinoma-Drug Profile 358

sorafenib tosylate-Drug Profile 359

SRX-2523-Drug Profile 363

STF-31-Drug Profile 365

STF-62247-Drug Profile 366

sunitinib malate-Drug Profile 367

Syrbactins-Drug Profile 371

tetraiodothyroacetic acid-Drug Profile 372

tivozanib-Drug Profile 373

TLC-388-Drug Profile 376

TRC-105-Drug Profile 378

trebananib-Drug Profile 381

TVI-Kidney-1-Drug Profile 385

Vaccine for Urogenital Cancers-Drug Profile 386

Vaccine to Target Prostate Specific Membrane Antigen for Renal Cell Carcinoma-Drug Profile 387

varlilumab-Drug Profile 388

VB-111-Drug Profile 390

X-379-Drug Profile 391

X-414-Drug Profile 392

ZD-6126-Drug Profile 393

Renal Cell Carcinoma-Recent Pipeline Updates 394

Renal Cell Carcinoma-Dormant Projects 574

Renal Cell Carcinoma-Discontinued Products 586

Renal Cell Carcinoma-Product Development Milestones 590

Featured News & Press Releases 590

Appendix 599

Methodology 599

Coverage 599

Secondary Research 599

Primary Research 599

Expert Panel Validation 599

Contact Us 599

Disclaimer 600

List of Tables

Number of Products under Development for Renal Cell Carcinoma, H1 2015 23

Number of Products under Development for Renal Cell Carcinoma-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 26

Number of Products under Development by Companies, H1 2015 (Contd..1) 27

Number of Products under Development by Companies, H1 2015 (Contd..2) 28

Number of Products under Development by Companies, H1 2015 (Contd..3) 29

Number of Products under Development by Companies, H1 2015 (Contd..4) 30

Number of Products under Development by Companies, H1 2015 (Contd..5) 31

Number of Products under Development by Companies, H1 2015 (Contd..6) 32

Number of Products under Investigation by Universities/Institutes, H1 2015 34

Comparative Analysis by Late Stage Development, H1 2015 35

Comparative Analysis by Clinical Stage Development, H1 2015 36

Comparative Analysis by Early Stage Development, H1 2015 37

Comparative Analysis by Unknown Stage Development, H1 2015 38

Products under Development by Companies, H1 2015 39

Products under Development by Companies, H1 2015 (Contd..1) 40

Products under Development by Companies, H1 2015 (Contd..2) 41

Products under Development by Companies, H1 2015 (Contd..3) 42

Products under Development by Companies, H1 2015 (Contd..4) 43

Products under Development by Companies, H1 2015 (Contd..5) 44

Products under Development by Companies, H1 2015 (Contd..6) 45

Products under Development by Companies, H1 2015 (Contd..7) 46

Products under Development by Companies, H1 2015 (Contd..8) 47

Products under Investigation by Universities/Institutes, H1 2015 48

Renal Cell Carcinoma-Pipeline by Acceleron Pharma, Inc., H1 2015 49

Renal Cell Carcinoma-Pipeline by Advenchen Laboratories, LLC, H1 2015 50

Renal Cell Carcinoma-Pipeline by Altor BioScience Corporation, H1 2015 51

Renal Cell Carcinoma-Pipeline by Ambrx, Inc., H1 2015 52

Renal Cell Carcinoma-Pipeline by Amgen Inc., H1 2015 53

Renal Cell Carcinoma-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 54

Renal Cell Carcinoma-Pipeline by Angiogene Pharmaceuticals Limited, H1 2015 55

Renal Cell Carcinoma-Pipeline by arGEN-X BV, H1 2015 56

Renal Cell Carcinoma-Pipeline by Argos Therapeutics, Inc., H1 2015 57

Renal Cell Carcinoma-Pipeline by Astellas Pharma Inc., H1 2015 58

Renal Cell Carcinoma-Pipeline by Bayer AG, H1 2015 59

Renal Cell Carcinoma-Pipeline by Beta Pharma, Inc., H1 2015 60

Renal Cell Carcinoma-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 61

Renal Cell Carcinoma-Pipeline by Biogenomics Limited, H1 2015 62

Renal Cell Carcinoma-Pipeline by Bionomics Limited, H1 2015 63

Renal Cell Carcinoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 64

Renal Cell Carcinoma-Pipeline by Boston Biomedical, Inc., H1 2015 65

Renal Cell Carcinoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 66

Renal Cell Carcinoma-Pipeline by Caladrius Biosciences, Inc. , H1 2015 67

Renal Cell Carcinoma-Pipeline by Calithera Biosciences, Inc., H1 2015 68

Renal Cell Carcinoma-Pipeline by Celldex Therapeutics, Inc., H1 2015 69

Renal Cell Carcinoma-Pipeline by Celltrion, Inc., H1 2015 70

Renal Cell Carcinoma-Pipeline by Cerulean Pharma, Inc., H1 2015 71

Renal Cell Carcinoma-Pipeline by Chipscreen Biosciences Ltd, H1 2015 72

Renal Cell Carcinoma-Pipeline by Conkwest, Inc., H1 2015 73

Renal Cell Carcinoma-Pipeline by CureTech Ltd., H1 2015 74

Renal Cell Carcinoma-Pipeline by Cytune Pharma SAS, H1 2015 75

Renal Cell Carcinoma-Pipeline by Eisai Co., Ltd., H1 2015 76

Renal Cell Carcinoma-Pipeline by Eli Lilly and Company, H1 2015 77

Renal Cell Carcinoma-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 78

Renal Cell Carcinoma-Pipeline by Exelixis, Inc., H1 2015 79

Renal Cell Carcinoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 80

Renal Cell Carcinoma-Pipeline by Genor BioPharma Co., Ltd., H1 2015 81

Renal Cell Carcinoma-Pipeline by GenSpera, Inc., H1 2015 82

Renal Cell Carcinoma-Pipeline by GlaxoSmithKline Plc, H1 2015 83

Renal Cell Carcinoma-Pipeline by Hemispherx Biopharma, Inc., H1 2015 84

Renal Cell Carcinoma-Pipeline by Hospira, Inc., H1 2015 85

Renal Cell Carcinoma-Pipeline by Hutchison MediPharma Limited, H1 2015 86

Renal Cell Carcinoma-Pipeline by immatics biotechnologies GmbH, H1 2015 87

Renal Cell Carcinoma-Pipeline by Immune Design Corp., H1 2015 88

Renal Cell Carcinoma-Pipeline by Immunicum AB, H1 2015 89

Renal Cell Carcinoma-Pipeline by ImmunoGen, Inc., H1 2015 90

Renal Cell Carcinoma-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 91

Renal Cell Carcinoma-Pipeline by InteRNA Technologies B.V., H1 2015 92

Renal Cell Carcinoma-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 93

Renal Cell Carcinoma-Pipeline by KAHR medical Ltd., H1 2015 94

Renal Cell Carcinoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 95

Renal Cell Carcinoma-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 96

Renal Cell Carcinoma-Pipeline by Lpath, Inc., H1 2015 97

Renal Cell Carcinoma-Pipeline by Mabion SA, H1 2015 98

Renal Cell Carcinoma-Pipeline by MacroGenics, Inc., H1 2015 99

Renal Cell Carcinoma-Pipeline by MediaPharma s.r.l., H1 2015 100

Renal Cell Carcinoma-Pipeline by MediGene AG, H1 2015 101

Renal Cell Carcinoma-Pipeline by MedImmune, LLC, H1 2015 102

Renal Cell Carcinoma-Pipeline by Merck & Co., Inc., H1 2015 103

Renal Cell Carcinoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 104

Renal Cell Carcinoma-Pipeline by Mologen AG, H1 2015 105

Renal Cell Carcinoma-Pipeline by NewLink Genetics Corporation, H1 2015 106

Renal Cell Carcinoma-Pipeline by Novartis AG, H1 2015 107

Renal Cell Carcinoma-Pipeline by Omeros Corporation, H1 2015 108

Renal Cell Carcinoma-Pipeline by Oncobiologics, Inc., H1 2015 109

Renal Cell Carcinoma-Pipeline by OncoMax, H1 2015 110

Renal Cell Carcinoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 111

Renal Cell Carcinoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 112

Renal Cell Carcinoma-Pipeline by Panacea Biotec Limited, H1 2015 113

Renal Cell Carcinoma-Pipeline by Panacela Labs, Inc., H1 2015 114

Renal Cell Carcinoma-Pipeline by Peloton Therapeutics, Inc., H1 2015 115

Renal Cell Carcinoma-Pipeline by Pfizer Inc., H1 2015 116

Renal Cell Carcinoma-Pipeline by Pono Pharma, H1 2015 117

Renal Cell Carcinoma-Pipeline by Prima BioMed Ltd., H1 2015 118

Renal Cell Carcinoma-Pipeline by PsiOxus Therapeutics Limited, H1 2015 119

Renal Cell Carcinoma-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 120

Renal Cell Carcinoma-Pipeline by Seattle Genetics, Inc., H1 2015 121

Renal Cell Carcinoma-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 122

Renal Cell Carcinoma-Pipeline by Taiwan Liposome Company, Ltd., H1 2015 123

Renal Cell Carcinoma-Pipeline by TC BioPharm Limited, H1 2015 124

Renal Cell Carcinoma-Pipeline by Theravectys S.A., H1 2015 125

Renal Cell Carcinoma-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 126

Renal Cell Carcinoma-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 127

Renal Cell Carcinoma-Pipeline by TVAX Biomedical, Inc., H1 2015 128

Renal Cell Carcinoma-Pipeline by Vascular Biogenics Ltd., H1 2015 129

Assessment by Monotherapy Products, H1 2015 130

Assessment by Combination Products, H1 2015 131

Number of Products by Stage and Target, H1 2015 133

Number of Products by Stage and Mechanism of Action, H1 2015 139

Number of Products by Stage and Route of Administration, H1 2015 144

Number of Products by Stage and Molecule Type, H1 2015 146

Renal Cell Carcinoma Therapeutics-Recent Pipeline Updates, H1 2015 403

Renal Cell Carcinoma-Dormant Projects, H1 2015 583

Renal Cell Carcinoma-Dormant Projects (Contd..1), H1 2015 584

Renal Cell Carcinoma-Dormant Projects (Contd..2), H1 2015 585

Renal Cell Carcinoma-Dormant Projects (Contd..3), H1 2015 586

Renal Cell Carcinoma-Dormant Projects (Contd..4), H1 2015 587

Renal Cell Carcinoma-Dormant Projects (Contd..5), H1 2015 588

Renal Cell Carcinoma-Dormant Projects (Contd..6), H1 2015 589

Renal Cell Carcinoma-Dormant Projects (Contd..7), H1 2015 590

Renal Cell Carcinoma-Dormant Projects (Contd..8), H1 2015 591

Renal Cell Carcinoma-Dormant Projects (Contd..9), H1 2015 592

Renal Cell Carcinoma-Dormant Projects (Contd..10), H1 2015 593

Renal Cell Carcinoma-Dormant Projects (Contd..11), H1 2015 594

Renal Cell Carcinoma-Discontinued Products, H1 2015 595

Renal Cell Carcinoma-Discontinued Products (Contd..1), H1 2015 596

Renal Cell Carcinoma-Discontinued Products (Contd..2), H1 2015 597

Renal Cell Carcinoma-Discontinued Products (Contd..3), H1 2015 598

List of Figures

Number of Products under Development for Renal Cell Carcinoma, H1 2015 23

Number of Products under Development for Renal Cell Carcinoma-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 25

Number of Products under Investigation by Universities/Institutes, H1 2015 33

Comparative Analysis by Clinical Stage Development, H1 2015 36

Comparative Analysis by Early Stage Products, H1 2015 37

Assessment by Monotherapy Products, H1 2015 130

Number of Products by Top 10 Targets, H1 2015 132

Number of Products by Stage and Top 10 Targets, H1 2015 132

Number of Products by Top 10 Mechanism of Actions, H1 2015 138

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 138

Number of Products by Top 10 Routes of Administration, H1 2015 143

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 143

Number of Products by Top 10 Molecule Types, H1 2015 145

Number of Products by Stage and Top 10 Molecule Types, H1 2015 145

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acceleron Pharma, Inc.

Advenchen Laboratories, LLC

Altor BioScience Corporation

Ambrx, Inc.

Amgen Inc.

Ampio Pharmaceuticals, Inc.

Angiogene Pharmaceuticals Limited

arGEN-X BV

Argos Therapeutics, Inc.

Astellas Pharma Inc.

Bayer AG

Beta Pharma, Inc.

Bio-Cancer Treatment International Limited

Biogenomics Limited

Bionomics Limited

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Caladrius Biosciences, Inc.

Calithera Biosciences, Inc.

Celldex Therapeutics, Inc.

Celltrion, Inc.

Cerulean Pharma, Inc.

Chipscreen Biosciences Ltd

Conkwest, Inc.

CureTech Ltd.

Cytune Pharma SAS

Eisai Co., Ltd.

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Genor BioPharma Co., Ltd.

GenSpera, Inc.

GlaxoSmithKline Plc

Hemispherx Biopharma, Inc.

Hospira, Inc.

Hutchison MediPharma Limited

immatics biotechnologies GmbH

Immune Design Corp.

Immunicum AB

ImmunoGen, Inc.

Inbiopro Solutions Pvt. Ltd.

InteRNA Technologies B.V.

Jiangsu Hengrui Medicine Co., Ltd.

KAHR medical Ltd.

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Lpath, Inc.

Mabion SA

MacroGenics, Inc.

MediaPharma s.r.l.

MediGene AG

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Mologen AG

NewLink Genetics Corporation

Novartis AG

Omeros Corporation

Oncobiologics, Inc.

OncoMax

Ono Pharmaceutical Co., Ltd.

Onyx Pharmaceuticals, Inc.

Panacea Biotec Limited

Panacela Labs, Inc.

Peloton Therapeutics, Inc.

Pfizer Inc.

Pono Pharma

Prima BioMed Ltd.

PsiOxus Therapeutics Limited

Rexahn Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Syndax Pharmaceuticals, Inc.

Taiwan Liposome Company, Ltd.

TC BioPharm Limited

Theravectys S.A.

Threshold Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

TVAX Biomedical, Inc.

Vascular Biogenics Ltd.

Renal Cell Carcinoma Therapeutic Products under Development, Key Players in Renal Cell Carcinoma Therapeutics, Renal Cell Carcinoma Pipeline Overview, Renal Cell Carcinoma Pipeline, Renal Cell Carcinoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com